BioSpace News Archive

QurAlis Corporation announced the opening of its European Union headquarters in Leiden, The Netherlands.

Pulmocide Ltd. today announced that Dan Burgess, Chairman and CEO, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 from 5:00pm – 5:25pm PT in San Francisco.

STRATA Skin Sciences, Inc. announced that it has received a notification letter from Nasdaq Stock Market LLC that the Company has been granted a 180-day extension, or until June 24, 2024, to regain compliance with Nasdaq’s minimum bid price rule.

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Remix Therapeutics (Remix) today announced the close of a $60 million financing led by The Column Group.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT in San Francisco, CA.

Star Therapeutics today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.

Cardio Diagnostics Holdings, Inc. announced that the American Medical Association has granted and assigned a dedicated Current Procedural Terminology Proprietary Laboratory Analysis code, 0439U, for the company’s AI-driven coronary heart disease event risk assessment test, Epi+Gen CHD.